Randomized trial shows co-mutations affect overall survival in adults with NPM1 mutated AML, suggesting therapy strategies.
Key Points
NPM1 mutated AML patients exhibited heterogeneous outcomes based on co-mutation profiles, influencing treatment decisions.
Adverse co-mutations such as FLT3-ITD were linked to poor prognosis, while mutations like IDH1 improved outcomes in specific combinations.
Next-generation sequencing facilitated accurate diagnosis and risk stratification to guide recommendations for allo-HSCT after remission therapy settings and outcomes support optimization efforts in treatment planning.